Gene supplementation therapies, favouring adeno-associated viruses (AAVs) as delivery vectors, are expanding the treatment options for neurological disorders [47], and an AAV gene therapy has been recently proven to be safe and effective in a neurodevelopmental disorder, aromatic L-amino acid decarboxylase deficiency [48]. This evidence concerns the gene DDC and neurodevelopmental disorder.